期刊
PROTEOMICS CLINICAL APPLICATIONS
卷 12, 期 5, 页码 -出版社
WILEY-V C H VERLAG GMBH
DOI: 10.1002/prca.201700164
关键词
ASD; early diagnosis; mass spectrum; serum biomarker
资金
- National Natural Science Foundation of China [81671445]
- Key Science and Technology Program of Shaanxi province [2015SF166]
- Fundamental Research Funds for the Central Universities [XJJ2016079]
PurposeAutism spectrum disorder (ASD) is a neurological and developmental disorder that begins early in childhood and lasts throughout one's life. Early diagnosis is essential for ASD since early treatment can enable children with ASD to make significant gains in language and social skills, but remains challenging since there are currently no specific biomarkers of ASD. This study is aimed to identify serum biomarkers for ASD. Experimental designSerum of Han Chinese children with ASD (n=68) and age-matched healthy controls (n=80) is analyzed using magnetic bead-based separation combined with mass spectrum. ResultsEight potential ASD serum biomarker peaks (m/z: 3886.69, 7775.12, 2381.71, 6638.63, 3319.17, 894.34, 4968.59, and 5910.53) with higher expression in ASD group are further identified as peptide regions of plasma serine protease inhibitor precursor (SERPINA5), platelet factor 4 (PF4), fatty acid binding protein 1(FABP1), apolipoprotein C-I precursor (APOC1), alpha-fetoprotein precursor (AFP), carboxypeptidase B2 (CPB2), trace amine-associated receptor 6 (TAAR6), and isoform1 of fibrinogen alpha chain precursor (FGA). The expression of identified proteins is validated by enzyme-linked immunosorbent assay (ELISA). Conclusions and medical relevanceThese findings reveal the exceptional disease etiology of ASD from a serum proteomic perspective, and the identified proteins might be potential biomarkers for ASD diagnosis.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据